A clinical trial to study the effect of Pomegranate (Anar)fruit extract capsule in patients with Myocardial Infarction(MI)

Antioxidative Effect of Punica Granatum (pomegranate) on Biochemical Parameters in Patients with Myocardial Infarction: A Double Blind Placebo Controlled Trial - NIL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/02/003420

Enrollment

Registered

2013-02-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Myocardial Infarction(MI) And Coronary Artery Disease(CAD)

Interventions

Intervention1: The active drug will have Punica granatum (pomegranate) extract of whole fruit.: Whole Pomegranate fruit extract Capsule is a food supplement which is manufactured by M/S Pharmanza Herb

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria I. Myocardial infarction as per signs and symptoms: Chest pain (typically down the left arm or left side of the neck), shortness of breath, nausea, sweating, anxiety, palpitations. (Diagnosed by clinical staff from Department of Medicine, VCSGGIMS&R) Confirmatory tests I. E.C.G. with changes - Q and ST segment elevation of 1mm or more in two neighboring leads II. Creatinin kinase MB (CK-MB) level more than the reference range III. Troponin I Or Troponin T level more than the reference range

Exclusion criteria

Exclusion criteria: Exclusion Criteria I.Patients with acute illness, pregnant, lactating, and postoperative patients. II.Patients with CNS disorders, systemic chronic diseases like renal failure, chronic hepatic disease, poorly controlled diabetes, or congestive heart failure.

Design outcomes

Primary

Measure	Time frame
Oxidative stress and CAD are main cause for the MI. Natural Antioxidants and Polyphenols presents in Pomegranate fruit will provide the prognostic significance against the oxidative stress. There may by improvement in the disease condition, which may be confirmed by quantitative estimation of biochemical markers with pre and post Pomegranate fruit extract and placebo after one month.Timepoint: 1.Literature review- 1 month 2.Protocol preparation- 1 month 3.Drug development-4 months 4.Drug trial-6 months 5.Data compilation & publication-2 months.	—

Measure

Time frame

Oxidative stress and CAD are main cause for the MI. Natural Antioxidants and Polyphenols presents in Pomegranate fruit will provide the prognostic significance against the oxidative stress. There may by improvement in the disease condition, which may be confirmed by quantitative estimation of biochemical markers with pre and post Pomegranate fruit extract and placebo after one month.Timepoint: 1.Literature review- 1 month 2.Protocol preparation- 1 month 3.Drug development-4 months 4.Drug trial-6 months 5.Data compilation & publication-2 months.

—

Secondary

Measure	Time frame
ADRs/AEs of Pomogrenate extract with other anti anginal drugs if anyTimepoint: one month	—

Countries

India

Contacts

Public ContactDr Monika Pathania

V.C.S.G. Government Institute of Medical Science and Research,Srikot- Pauri Garhwal,Uttarakhand

vijaythawani@rediffmail.com07579039260

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026